Adrenal Cortex Diseases Clinical Trial
Official title:
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
Verified date | January 2019 |
Source | Bnai Zion Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In adrenal tumors, the investigators will examine if there is any correlation between WIESS criteria, prognosis of the tumor, and the different labeling index of the following proliferation biomarkers: MCM3, MCM2, KI-67, P53, NEUROPILIN -1, METALLOTHIONEIN, SEMAPHORIN-3A.
Status | Active, not recruiting |
Enrollment | 70 |
Est. completion date | December 2019 |
Est. primary completion date | July 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - adrenal carcinoma - adrenal adenoma - normal adrenal tissue Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bnai Zion Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MCM3 expression | Difference in MCM3 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Primary | MCM2 expression | Difference in MCM2 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Primary | P53 expression | Difference in P53 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Primary | NEUROPILIN -1 expression | Difference in NEUROPILIN -1 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Primary | METALLOTHIONEIN expression | Difference in METALLOTHIONEIN labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Primary | SEMAPHORIN-3A expression | Difference in SEMAPHORIN-3A labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Primary | E-caderein expression | Difference in E-caderein labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Secondary | KI67 | Difference in Ki67 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma | 1 year | |
Secondary | Prognosis | Correlation between the labeling index of each biomarker, WIESS criteria and prognosis of the tumor. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01255137 -
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
|
Phase 2 | |
Completed |
NCT00768365 -
Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma
|
N/A | |
Completed |
NCT00071058 -
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
|
Phase 2 |